Godavari Biorefineries Secures Japan Patent for Antiviral Compounds

Godavari Biorefineries Limited has secured a Japan patent for antiviral compounds, marking a fresh step in its expanding life sciences research.

The patent, granted by the Japan Patent Office (JPO), covers the second medical use of its lead molecule MSP22 and related derivatives for treating viral infections by targeting V-ATPase activity.

This Japan patent for antiviral compounds strengthens the company’s intellectual property in a key global market. The invention focuses on compounds that inhibit Vacuolar ATPase (V-ATPase), a host-cell mechanism that viruses use to enter and replicate within cells. By targeting this pathway, the research opens the door to a broader antiviral strategy that may work across multiple virus families instead of a single strain.

Also Read: Advancing Interventional Radiology in India Through Collaboration

The innovation comes through Sathgen Therapeutics, the company’s biotechnology arm dedicated to turning research into therapies. The patent credits Dr. Maithili Athavale, Dr. Sandip Gavade, Dr. Prashant Kharkar, and Dr. Sangeeta Srivastava, highlighting the collaborative effort behind the discovery.

“Securing this patent in Japan reflects a natural extension of our ongoing work in drug discovery,” said Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries.

“As we progressed with our R&D efforts on lead molecules, we identified their potential to inhibit mechanisms such as V-ATPase, which are relevant in antiviral applications. Protecting this therapeutic use in a market like Japan is an important step in strengthening our intellectual property portfolio and advancing molecules with broader clinical potential,” added Somaiya.

“Research that targets the VATPase which is a critical cellular enzyme complex exploited by viruses could open new directions in antiviral therapy,” said Dr. Sangeeta Srivastava.

“This patent reflects our effort to translate scientific research into therapeutic approaches that could eventually address critical global health challenges,” added Srivastava.